Federal Law
-
Marijuana Rescheduling: The Good, the Bad, and the ‘Wait-and-See’
Author: Leticia Maskell, Emerge Law Clerk News broke last week that U.S. Health and Human Services (HHS) sent a letter…
-
Federal Trade Commission’s Proposed Rule on Deceptive Reviews
Authors: Jay Purcell, Shareholder; Kaci Hohmann, Attorney; Blake Marvis, Attorney; Leticia Maskell, Law Clerk Summary. On July 31, 2023, the…
-
Copyright Office Guidance Regarding Artificial Intelligence
Author: Sean Clancy*, Shareholder Understanding copyright law in the age of artificial intelligence can be complex and confusing. And it…
-
DEA Takes a Rare Step Forward for Telehealth
Author: Matt Brockmeier, Emerge Of Counsel Attorney The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the Act) amended…
-
PsychedeLinks – March 3, 2023
PsychedeLinks is a curated selection of top news stories impacting business, research, and culture in the psychedelics ecosystem, crafted by Emerge…
-
Critical Terms for Intellectual Property License Agreements (Part 2)
Author: Sean Clancy An audit provision is a clause in an intellectual property license agreement that provides the right for…
-
Beneficial Owners – New Reporting Rules
Authors: Kaci Hohmann and Delia Rojas, Attorneys at Emerge Law Group On September 30, 2022, the federal Financial Crimes Enforcement…
-
Residency Requirements Under Attack – Analysis of the First Circuit’s Opinion on the Dormant Commerce Clause’s Effect on Cannabis Residency Requirements
Author: Blake Marvis, Attorney at Emerge Law Group; Oregon Litigation Practice Group In August, the First Circuit Court of Appeals…
-
President Biden Pardons Those Convicted of Federal Marijuana Possession
President Biden Pardons Those Convicted of Federal Marijuana Possession; Seeks Review of Marijuana’s Schedule I Status Yesterday President Biden pardoned…
-
Critical Terms for Intellectual Property License Agreements (Part 1)
By: Sean Clancy Intellectual property (“IP”) license agreements come in many shapes and flavors. But all IP licenses boil down…
-
Right to Try (RTT) Laws: A Battle with Multiple Fronts
By: Kathryn Tucker, JD[1] Background We have been leading efforts to open access to the investigational psychedelic drug psilocybin for…
-
Update re AIMS et al. v. DEA: DEA Doubles Down in Denying Dying Patients Access to Psilocybin
By Kathryn Tucker, JD[1] In January 2021, Dr. Sunil Aggarwal, a respected palliative care physician and founder of the Advanced…
-
At DEA’s Door: The Battle to Open Access to Psilocybin Therapy for Peace and Comfort at the End of Life
By Kathryn Tucker, JD[1] On Mother’s Day 2022, my client Erinn Baldeschwiler, a young mother of two with Stage IV…
-
FREE Virtual Event Series – Deep Dive Into the Oregon Psilocybin Services Act: Federal Law Issues (Session 5)
Emerge Law Group is continuing its FREE virtual event series “Deep Dive Into the Oregon Psilocybin Services Act“! Session 5: Federal…
-
Efforts to Open Access to Psilocybin for Therapeutic Use with Those with Life Threatening Illness Continue
Emerge Law Group Special Counsel Kathryn Tucker submitted a Freedom of Information Act (“FOIA“) request to the Drug Enforcement Administration…
-
Lions and Tigers and Shell Companies, Oh My! Preparing Your Business for Federal Beneficial Ownership Reporting Requirements
By: Delia Rojas and Kaci Hohmann The Corporate Transparency Act (“CTA”), part of the federal Anti-Money Laundering Act of 2020,…
-
Establishing a Pathway to Access Psilocybin for Use with Patients with Advanced Illness: UPDATE
As counsel to Dr. Sunil Aggarwal of the Advanced Integrative Medical Science (“AIMS”) Institute we have been seeking authorization for…
-
New Federal Trademark Proceedings: What To Know
On December 18, 2021, rules promulgated under the Trademark Modernization Act of 2020 (“Act”) went into effect. The rules, among…
-
Landmark Petition to Reschedule Psilocybin filed with DEA
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on…
-
Ninth Circuit ducks merits in nation’s first legal challenge to allow access to psilocybin in end-of-life care under “Right-To-Try” laws
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research…
-
Why I Do What I Do: Representing patients with advanced illness
I represent Erinn Baldeschwiler in AIMS et al v DEA. Erinn is faced with advanced cancer, and the prospect of…
-
Psilocybin Therapy for Patients with Advanced Illness in Oregon
One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who…
-
Court Hears Argument in Landmark Case Seeking to Open Access to Psilocybin Therapy
Nation’s First Legal Challenge to Allow Psilocybin Therapy in End-of-Life Care Under “Right-To-Try” Law Heard by the Ninth Circuit Court…
-
California’s Aid in Dying Law Challenged in Federal Court for Discriminating Against Terminally Ill Patients with Physical Disabilities
Read Mercury News Article here: When the Aid-In-Dying Law Leaves You Out A number of Californians with terminal illnesses involving…